Skip to main content

Table 2 Synergistic combinations of targeted drugs in glioma tumor-initiating cells

From: Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells

Drugs

GSC11

GSC47

GSC20

GSC2

Erlotinib + Sorafenib

0.85 ± 0.23

1.30 ± 0.16

1.21 ± 0.26

1.04 ± 0.24

Lapatinib + Sorafenib

0.82 ± 0.27

1.17 ± 0.40

1.18 ± 0.05

1.32 ± 0.06

Erlotinib + U0126

0.98 ± 0.24

2.14 ± 0.75

0.73 ± 0.08

0.52 ± 0.31

Erlotinib + PD98059

NE

NE

0.79 ± 0.17

NE

Lapatinib + U0126

NE

NE

0.86 ± 0.12

NE

Erlotinib + BKM120

1.16 ± 0.19

NE

1.04 ± 0.24

0.71 ± 0.05

Sorafenib + U0126

0.67 ± 0.13

0.73 ± 0.09

1.20 ± 0.59

0.56 ± 0.30

  1. Chou and Talalay combination indices (CI) are shown as means ± 95 % confidence intervals of at least two independent experiments. Synergistic interactions were confirmed by three independent experiments. According to the original study by Chou and Talalay, CI <1, = 1; and >1 indicate synergistic, additive, and antagonistic, respectively. In this study, combination effect was thought to be synergistic when CI was less than 0.9
  2. NE Not examined
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us